Skip to main content

Month: June 2022

Bulletin from the annual general meeting of Hoylu AB (publ) on 10 June 2022

Bulletin from the annual general meeting of Hoylu AB (publ) on 10 June 2022 The annual general meeting of Hoylu AB (publ) (the “Company“) was held today, 10 June 2022, the resolutions were passed with required majority in accordance with the board’s published proposals. The main resolutions adopted by the meeting are set out below. Profit appropriation etc. The annual general Meeting approved the balance sheet and consolidated financial statements as of 31 December 2021 included in the annual report, as well as the income statement and consolidated income statement for the financial year 2021. The meeting resolved that no dividend shall be paid for the financial year 2021 and that the remaining funds shall be transferred to new account. The meeting granted all directors during the financial year of 2021 and the CEO discharge...

Continue reading

Form 8.3 – [LXI REIT PLC 09 06 2022] – CGWL

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LXI REIT PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [IDEAGEN PLC – 09 06 2022] – CGWL

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IDEAGEN PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDEAGEN PLC AS AN ASSOCIATE OF THE...

Continue reading

Form 8.3 – [BIFFA PLC – 09 06 2022] – CGWL

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree BIFFA PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations

PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and its affiliate company Venthera, Inc. (Venthera), today announced preliminary data from the Phase 1b trial of VT30 topical gel (BBP-681) in patients with venous, lymphatic and mixed venolymphatic lesions of the skin (VM, LM and VLM, respectively), which are rare genetic vascular anomalies driven by dysregulated activation of intracellular PI3K. The data are being shared in a virtual presentation to the International Society for the Study of Vascular Anomalies (ISSVA). “People living with cutaneous VMs and LMs can experience clinical complications including pain, bleeding, and impaired functioning of the affected area. To date, their treatment options are limited to interventional procedures and surgeries. We are pleased that...

Continue reading

Osino Announces Additional Wide and High-Grade Drill Intercepts, Twin Hills West Gold Project, Namibia

Figure 1 Twin Hills Gold Project Main Mineralized Zones (Bulge, Twin Hills Central, Clouds and Twin Hills West)Figure 2 Location of THW drill collars and recent assay results superimposed on ground magnetic image.Figure 3 Section 1 through Twin Hills West, showing at least two zones of mineralization.Figure 4 Section 2 through Twin Hills West, showing wide zones of mineralization.HighlightsLatest drill assays from infill and step-out drilling at Twin Hills West (“THW”) include:OKR497: 5m @ 10.11g/t (170-175m) and 20m @ 1.03g/t (188-208m) OKD413: 40m @ 1.66g/t (43-83m) incl. 21m @ 2.66g/t OKR451: 28m @ 1.64g/t (103-131m) and 5m @ 0.69g/t (202-207m) OKR470: 42m @ 1.10g/t (126-168m) incl. 6m @ 1.36g/t and 26 @ 1.41g/t OKR476: 13m @ 3.41g/t (60-73m) OKR455: 41m @ 0.92g/t (70-111m) incl. 31m @ 1.14g/t OKR466: 34m @ 0.95g/t...

Continue reading

B2 Digital’s B2FS 165 (Saturday) to Kick Off the B2 Fighting Series on FITE

TAMPA, FL, June 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), is excited to announce that the B2 Fighting Series is now available on the FITE streaming media platform, with past B2FS events becoming available on the FITE+ subscription service beginning yesterday, June 9, and new fight nights appearing on FITE as live pay-per-view (PPV) events, beginning tomorrow, Saturday, June 11, when the B2 Fighting Series heads back to Birmingham, Alabama for a hard hitting night of MMA action at B2FS 165. What: B2 Fighting Series 165, Amateur and Professional LIVE MMA Where: Bill Harris Arena in Birmingham, Alabama When: Saturday, June 11. Doors open at 6 pm ET. PPV Broadcast starts at 7 pm ET on FITE+ Physical...

Continue reading

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

— Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior chemotherapy — Potential best-in-class therapy for ROS1-positive metastatic NSCLC and NTRK-positive advanced solid tumors SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted two Breakthrough Therapy Designations for investigational repotrectinib for the treatment of patients with ROS1-positive metastatic NSCLC who have received one prior line of ROS1...

Continue reading

AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market

PHILADELPHIA, June 10, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company on June 9, 2022 that Nasdaq has determined the Company has regained compliance with the requirements to remain listed in The Nasdaq Capital Market, as required by a hearing panel’s decision dated May 4, 2022, subject to a one-year Mandatory Panel Monitor of the Company’s ongoing compliance with such requirements. On May 31, 2022, the Company filed a Form 6-K (the “Filing”) with the SEC, including unaudited financial statements, and referencing the receipt of proceeds from the sale of the Company’s ordinary...

Continue reading

ESE to Exhibit its Technology and Gaming Simulators at Montreal’s Crescent Street Grand Prix Festival, June 16 to 18

VANCOUVER, British Columbia, June 10, 2022 (GLOBE NEWSWIRE) — ESE Entertainment Inc. (“ESE” or the “Company”) (TSXV: ESE) (OTCQB: ENTEF) is pleased to announce that its Digital Motorsports brand will be exhibiting at the Crescent Street Grand Prix Festival on June 16 to 18, 2022, during the Formula 1 Canadian Grand Prix. Since 1999, the historic festival has taken place on Crescent Street in downtown Montreal and is the epicenter for race fans during the Grand Prix week. Digital Motorsports will showcase their latest F1-inspired simulators on two separate activation sites right in the heart of crescent street. A total of four professional grade simulators will be linked via computer servers, enabling fans to race against each other on the virtual Circuit De Gilles Villeneuve racetrack in the latest F1-inspired cars. Daily time...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.